Metabolic Continuity in Cancer Vaccination
Vaccines · 15.11.2026 · 14 (11) · 986
DOI: 10.3390/vaccines14110986 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 15.11.2026. Verfasst von Subbaya Subramanian. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer vaccines can generate durable, tumor-specific T-cell responses, yet immunogenicity remains an imperfect surrogate for tumor control. An important, incompletely characterized contributor may be the metabolic fitness of the vaccine-induced immune response. Dendritic-cell activation, T-cell clonal expansion, effector differentiation, trafficking, tissue residency, tumor entry, cytotoxicity, and memory formation each impose distinct bioenergetic and biosynthetic requirements. These requirements are progressively challenged in tumors by nutrient competition, hypoxia, lactate and acidosis, adenosine, lipid stress, amino-acid depletion, mitochondrial dysfunction, and metabolically adapted suppressive cells. Here, we use metabolic continuity as a design principle for cancer vaccination: successful therapy requires preservation of metabolic competence from antigen presentation through intratumoral tumor killing and durable memory. We further use the term shared nutrient-dependency paradox to highlight a translational problem: pathways considered attractive tumor targets, including amino-acid transport and mTOR-linked nutrient sensing, may also be required by newly activated antitumor T cells. LAT1/SLC7A5 provides a particularly instructive example because it supports large neutral amino-acid uptake in both malignant cells and activated cytotoxic lymphocytes. We argue that metabolic interventions should therefore be judged by a vaccine-specific metabolic therapeutic index, not by tumor-cell growth inhibition alone. The most rational combinations will exploit differences in metabolic plasticity, cellular selectivity, anatomical compartment, and treatment timing. Incorporating metabolic biomarkers into vaccine trials could shift cancer vaccination from an antigen-centric intervention toward a metabolically engineered immune response.
Zitieren
APA
Subramanian, S. (2026). Metabolic Continuity in Cancer Vaccination. Vaccines, 14(11), 986. https://doi.org/10.3390/vaccines14110986
Vancouver
Subramanian S. Metabolic Continuity in Cancer Vaccination. Vaccines. 2026;14(11):986. doi:10.3390/vaccines14110986
BibTeX
@article{Subramanian2026,
author = {Subramanian, Subbaya},
title = {Metabolic Continuity in Cancer Vaccination},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {11},
pages = {986},
doi = {10.3390/vaccines14110986}
}
EUVIMED